| Description | BCN-PEG3-Val-Cit is a PEG-based linker commonly employed in PROTAC synthesis[1]. Additionally, it serves as a cleavable 3 unit PEG linker in the production of antibody-drug conjugates (ADCs)[2]. |
| In vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[2]. |
| molecular weight | 653.76 |
| Molecular formula | C31H51N5O10 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562. 2. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. |